tiprankstipranks
Trending News
More News >
Cencora (COR)
NYSE:COR
US Market

Cencora (COR) Earnings Dates, Call Summary & Reports

Compare
1,131 Followers

Earnings Data

Report Date
May 06, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
4.87
Last Year’s EPS
4.42
Same Quarter Last Year
Based on 9 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Feb 04, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call communicated strong execution and clear growth momentum: revenue, gross profit, adjusted EPS and consolidated operating income all increased, leadership completed a strategic MSO acquisition (OneOncology), and management raised both revenue and operating income guidance for fiscal 2026. Key drivers included specialty growth (including GLP-1s), RCA outperformance, and MSO expansion. Near-term pressures were acknowledged — higher operating and interest expenses from acquisitions and financing, a seasonal negative free cash flow quarter, timing-related international operating income weakness, and customer off-boarding — but management framed many as transitory or expected to normalize over the year. Overall, positive operational trends and upgraded guidance outweigh the near-term challenges.
Company Guidance
Cencora raised and clarified fiscal 2026 guidance: reaffirming adjusted diluted EPS of $17.45–$17.75 (Q1 adj. EPS $4.08, +9%), raising consolidated revenue growth to 7%–9% (Q1 revenue $85.9B, +5.5%) and consolidated operating income growth to 11.5%–13.5% (Q1 operating income $1.1B, +12%). Key segment guidance includes US Healthcare Solutions operating income growth of 14%–16% (Q1 US revenue $76.2B, +5%; US operating income $831M, +21%), International revenue growth 7%–9% as‑reported (6%–8% constant currency) with no change to international operating income guidance, and Other revenue growth of 1%–5% with Other operating income expected flat year‑over‑year. Financial assumptions include interest expense of $480M–$500M (up from $315M–$335M; Q1 net interest $72M and Q2 expected to be about 2x Q1), a full‑year effective tax rate of ~20% (Q1 19%), cash of $1.8B, negative adjusted free cash flow of $2.4B in Q1 (vs. -$2.8B prior year) and full‑year adj. FCF ~ $3B, paused share repurchases with reported Q1 diluted share count 195.3M (company expects ~105.5M full‑year), OneOncology expected to be roughly neutral to adjusted EPS in its first 12 months but to boost operating income and to contribute ~ $30M of other income (with related noncontrolling interest impacts largely offset).
Revenue Growth and Raised Top-Line Guidance
Consolidated revenue of $85.9 billion, up 5.5% year-over-year. Company raised full-year consolidated revenue growth guidance to 7%–9% (from prior 5%–7%), reflecting stronger growth across reportable segments and contributions from OneOncology.
Earnings and Operating Income Expansion
Adjusted diluted EPS of $4.08 in the quarter, up 9% year-over-year. Consolidated operating income increased 12% year-over-year. Management raised full-year consolidated adjusted operating income growth guidance to 11.5%–13.5% (from 8%–10%).
US Healthcare Solutions Strength
US Healthcare Solutions revenue $76.2 billion, up 5%. US segment operating income increased 21% to $831 million, driven by specialty growth, strong health system volumes, physician practice sales, RCA contribution and early OneOncology results. Full-year US operating income guidance raised to 14%–16%.
Gross Profit and Margin Improvement
Consolidated gross profit of $3.0 billion, up 18% year-over-year. Gross profit margin improved to 3.48%, a 37 basis point increase, with RCA acquisition cited as a margin contributor.
Specialty Product Momentum (GLP-1s)
Continued strong sales in GLP-1 products, which grew by $1.0 billion or 11% versus the prior-year quarter, contributing to US segment strength.
Strategic Acquisitions and MSO Expansion
Completed acquisition of the majority of remaining equity interest in OneOncology (ownership increased from 35% to 92% with ~8% retained by practices/management) and celebrated one-year anniversary of Retina Consultants of America (RCA). OneOncology expected to be neutral to adjusted EPS in first 12 months and to be a meaningful operating income contributor thereafter.
Improving Full-Year Cash Flow Outlook
Negative adjusted free cash flow of $2.4 billion in the quarter (seasonal working capital), improved versus negative $2.8 billion prior-year quarter. Company expects full-year adjusted free cash flow of approximately $3.0 billion as working capital dynamics unwind.

Cencora (COR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

COR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 06, 2026
2026 (Q2)
4.87 / -
4.42
Feb 04, 2026
2026 (Q1)
4.05 / 4.08
3.739.38% (+0.35)
Nov 05, 2025
2025 (Q4)
3.79 / 3.84
3.3414.97% (+0.50)
Aug 06, 2025
2025 (Q3)
3.85 / 4.00
3.3419.76% (+0.66)
May 07, 2025
2025 (Q2)
4.12 / 4.42
3.816.32% (+0.62)
Feb 05, 2025
2025 (Q1)
3.50 / 3.73
3.2813.72% (+0.45)
Nov 06, 2024
2024 (Q4)
3.23 / 3.34
2.8616.78% (+0.48)
Jul 31, 2024
2024 (Q3)
3.22 / 3.34
2.9214.38% (+0.42)
May 01, 2024
2024 (Q2)
3.69 / 3.80
3.58.57% (+0.30)
Jan 31, 2024
2024 (Q1)
2.90 / 3.28
2.7121.03% (+0.57)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

COR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 04, 2026
$361.13$329.41-8.78%
Nov 05, 2025
$343.38$352.81+2.75%
Aug 06, 2025
$290.83$282.30-2.93%
May 07, 2025
$288.74$302.41+4.74%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cencora (COR) report earnings?
Cencora (COR) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
    What is Cencora (COR) earnings time?
    Cencora (COR) earnings time is at May 06, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is COR EPS forecast?
          COR EPS forecast for the fiscal quarter 2026 (Q2) is 4.87.